NANO-X IMAGING LTD: New Clinical Study Data, Featuring Nanox.AI Cardiac Solution to Be Presented at SCCT 2026
Nanox Imaging Ltd. (NASDAQ: NNOX) said clinical study data on its Nanox.AI FDA-cleared cardiac AI solution (HealthCCSng) will be presented at SCCT 2026. The AI INFORM trial and a multi-site analysis will report agreement between AI-detected coronary artery calcium and expert assessment, according to abstracts from Brigham and Women’s Hospital and others.
How this was made
The 30-second read
Why it matters
The new SCCT abstracts provide additional clinical validation framing (AI INFORM trial and multi-site agreement with expert visual assessment) that can support the company’s evidence narrative, but the article lacks quantitative results or commercialization updates.
Market read
Traders may monitor for sentiment/volume around SCCT abstract presentation dates, but the text does not provide a hard financial catalyst.
What to watch
The release notes some referenced tech is under development/not cleared; traders should separate FDA-cleared HealthCCSng evidence from any non-cleared or exploratory claims discussed in the sponsored session.
Background
Nanox.AI’s FDA-cleared CT-based AI solutions (HealthCCSng/HealthOST/HealthFLD) are positioned as tools to detect incidental findings and enable preventive care.
Ticker impact
Nanox Imaging (Nanox.AI) will present multi-site AI INFORM trial and HealthCCSng agreement data at SCCT 2026, supporting FDA-cleared cardiac AI utility claims.
Likely limited near-term impact; any reaction would be sentiment-driven around the event window rather than a step-change in fundamentals.
The article discloses new abstract content (AI INFORM trial and multi-site agreement vs expert visual assessment) but provides no new efficacy metrics, regulatory decisions, or commercial contract/uptake data.
Market effects
Adds incremental clinical-evidence momentum for AI medical imaging/CT analytics providers, potentially supporting sector sentiment around preventive cardiology AI.
Primarily US academic/clinical validation narrative (Brigham and Women’s, MGH, UT Southwestern, Cedars-Sinai).
Could reinforce global adoption expectations for AI-assisted preventive care workflows, though no geography-specific commercialization is disclosed.
Counterpoint
Conference abstracts may not translate into near-term revenue; without disclosed effect sizes or endpoints, the market may discount the update.
Key entities
- companyNanox Imaging Ltd.
NASDAQ-listed medical imaging and AI analytics company; subject of the press release.
- productHealthCCSng
Nanox.AI FDA-cleared AI cardiac solution referenced in the SCCT abstracts.
- clinical_studyAI INFORM randomized trial
Multi-site trial described as featuring AI-detected coronary calcium to support preventive lipid-lowering therapy decisions.
- eventSCCT 2026
Society of Cardiovascular Computed Tomography annual meeting where the abstracts will be presented.
